Protein Kinase Inhibitors: all 15,278 studies that test it

Page 74 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Active, not recruitingNCT06683742Phase 3
• A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsActive, not recruitingNCT06682572Phase 2
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesActive, not recruitingNCT06671496Phase 3
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Active, not recruitingNCT06668064Phase 3
• Baricitinib for Refractory Takayasu ArteritisCompletedNCT06662721Phase 2
• Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomasActive, not recruitingNCT06654297Phase 1
• SPH3348 Tablets in a Single-center, Randomized, Open-label, Single-dose, Two-period, Two-sequence Crossover Design Food Effect Study in Healthy Chinese SubjectsCompletedNCT06652997Phase 1
• Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Active, not recruitingNCT06647732Phase 2
• A Study of [14C]-LY3866288 in Healthy ParticipantsCompletedNCT06644378Phase 1
• A Study of LY3866288 in Healthy ParticipantsCompletedNCT06641037Phase 1
• Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsActive, not recruitingNCT06635447Phase 3
• A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)CompletedNCT06625827Phase 1
• A Study of Filgotinib in Korean Participants With Rheumatoid ArthritisCompletedNCT06625242Phase 4
• A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT06624059Phase 3
• Clinical Trial of FCN-437c Capsule in Patients With Hepatic InsufficiencyCompletedNCT06620731Phase 1
• A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult SubjectsCompletedNCT06619951Phase 1
• A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic TherapiesCompletedNCT06616415Phase 4
• Effect of Capivasertib on ctDNA in ER Positive Breast CancerWithdrawnNCT06613516Phase 2
• Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast CancerActive, not recruitingNCT06612203Phase 1/2
• A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)TerminatedNCT06602453Phase 2
• Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLCompletedNCT06601504Phase 2
• To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment SubjectsCompletedNCT06598956Phase 1
• Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVIDActive, not recruitingNCT06597396Phase 2
• A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001CompletedNCT06588738Phase 3
• A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)CompletedNCT06586671Phase 1
• A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT06586112Phase 3
• Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT06585202Phase 2
• Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT LymphomaActive, not recruitingNCT06583837Phase 2
• Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRCActive, not recruitingNCT06578559Phase 2
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLActive, not recruitingNCT06578247Phase 3
• A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy ParticipantsCompletedNCT06568458Phase 1
• Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy ParticipantsCompletedNCT06566768Phase 1
• The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic FunctionCompletedNCT06562946Phase 1
• A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy ParticipantsCompletedNCT06555081Phase 1
• A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisActive, not recruitingNCT06550076Phase 3
• Leniolisib for Immune Dysregulation in PIDsCompletedNCT06549114Phase 2
• Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary InjuryActive, not recruitingNCT06548802Phase 1/2
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• Retinol Binding Protein 4 Protein in Alopecia Areata Treated With BarcitinibActive, not recruitingNCT06545110Phase 1
• Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLActive, not recruitingNCT06541665Phase 1
• DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)CompletedNCT06539195Phase 2
• A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid TumorsActive, not recruitingNCT06533059Phase 1
• A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerActive, not recruitingNCT06532331Phase 1
• Deucravacitinib RosaceaWithdrawnNCT06532136Phase 2
• Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult SubjectsCompletedNCT06529445Phase 1
• Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerCompletedNCT06525246Phase 1
• GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT06522386Phase 2
• Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)WithdrawnNCT06522360Phase 2
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.CompletedNCT06519968Phase 1
• Avelumab and M1774 in ARID1A-mutated Endometrial CancerActive, not recruitingNCT06518564Phase 2
• Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal HyperbilirubinemiaCompletedNCT06517862Phase 4
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)Active, not recruitingNCT06516965Phase 3
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)Active, not recruitingNCT06516952Phase 3
• Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung AdenocarcinomaTerminatedNCT06516887Phase 1/2
• AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)CompletedNCT06511895Phase 2
• AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)CompletedNCT06511869Phase 2
• A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 TabletsTerminatedNCT06507891Phase 1/2
• Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Active, not recruitingNCT06506955Phase 2/3
• A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy ParticipantsCompletedNCT06505265Phase 1
• Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT06504199Phase 2
• A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT06498986Phase 2
• A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated CancersActive, not recruitingNCT06496568Phase 1
• Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationActive, not recruitingNCT06495918Phase 3
• Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous CarcinomaCompletedNCT06494189Phase 1
• Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)Active, not recruitingNCT06494150Phase 2
• A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy ParticipantsCompletedNCT06493409Phase 1
• Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT06492915Phase 2
• Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With HemoblastosisActive, not recruitingNCT06475820Phase 2/3
• A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute LeukemiasWithdrawnNCT06474663Phase 1
• Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host DiseaseActive, not recruitingNCT06462469Phase 4
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisActive, not recruitingNCT06461897Phase 3
• Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered RadotinibCompletedNCT06461078Phase 1
• Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid LeukemiaSuspendedNCT06454409Phase 1
• Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06447636Phase 2
• Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast CancerActive, not recruitingNCT06447623Phase 3
• Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT06445907Phase 1
• A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)CompletedNCT06444204Phase 1
• Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian SubjectsCompletedNCT06444191Phase 1
• A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)CompletedNCT06442436Phase 1
• A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy ParticipantsCompletedNCT06441318Phase 1
• TGRX-326 Pharmacokinetic Mass BalanceCompletedNCT06438367Phase 1
• Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With AsthmaCompletedNCT06435273Phase 2
• A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant DermatomyositisCompletedNCT06433999Phase 2
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2
• Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I MutationCompletedNCT06427811Phase 4
• Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRCStatus unknownNCT06427005Phase 2
• Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)WithdrawnNCT06424717Phase 2
• Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy SubjectsActive, not recruitingNCT06423261Phase 1
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06417814Phase 3
• BTX-A51 in Patients With Liposarcoma or CIC-rearranged SarcomaActive, not recruitingNCT06414434Phase 1
• A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyActive, not recruitingNCT06413706Phase 2
• Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)TerminatedNCT06408168Phase 2
• Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)Active, not recruitingNCT06400225Phase 2
• Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal AdenocarcinomaWithdrawnNCT06398587Phase 2
• Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy ParticipantsCompletedNCT06397508Phase 1
• RVU120 in Patients With Intermediate or High-risk, Primary or Secondary MyelofibrosisTerminatedNCT06397313Phase 2
• The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric JunctionStatus unknownNCT06396585Phase 2
• The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related MyocarditisCompletedNCT06393972Phase 2
• JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsActive, not recruitingNCT06391944Phase 2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingNCT06390865Phase 2

← Protein Kinase Inhibitors overview